Experimental Drug Bests Chemo in Non-Small Cell Lung Cancer Study
Quick ReadBetter response, progression-free survival time seen with Tarceva in trial patients
Photos
A drug designed to treat certain patients with non-small cell lung cancer boosts survival time without progression of cancer by several months, according to a new study.
The findings reveal that the drug, known as erlotinib (brand name Tarceva), doesn't just boost lifespan, said Dr. Neal E. Ready, associate professor of medical oncology at Duke Cancer Institute, who was not involved with the...
